Hyperthermia in the pediatric intensive care unit – is it malignant hyperthermia?

Schleelein, Laura E.; Litman, Ronald S.

doi:10.1111/j.1460-9592.2009.03120.x

Cited by 4 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The variability in the onset of clinical symptoms and lab values makes the diagnosis of MH difficult. Traditionally, the onset of MH is known to be 30 minutes to 1.5 hours after exposure to the inciting agent with the most rapid onset shown to be after halothane (20±5 minutes) compared to isoflurane (48±24 minutes) [ 9 ]. Interestingly in our case, signs and symptoms of MH began to manifest approximately six hours after isoflurane initiation.…”

Section: Discussionmentioning

confidence: 99%

Inhalational Anesthesia for Near-fatal Pediatric Asthma Complicated by Malignant Hyperthermia

Pasrija¹,

Assioun²,

Sallam³

et al. 2021

Cureus

View full text Add to dashboard Cite

Acute severe asthma is a commonly encountered condition in the pediatric emergency room and the pediatric intensive care unit (PICU). Its treatment involves the use of bronchodilatory agents acting on different receptors, steroids to reduce ongoing inflammation, and non-invasive or invasive mechanical ventilation to offload the increased work of breathing from the respiratory muscles. Patients refractory to these therapies may require the use of inhaled anesthetic agents and extracorporeal gas exchange (ECMO) for life-threatening asthma exacerbations. Depending on institutional protocols, the use of these therapies may vary. The use of inhaled anesthetic agents for asthma management in the PICU is infrequent and is limited to centers with specialized equipment. Commonly encountered side effects include hypotension, arrhythmias, and delirium. Malignant hyperthermia (MH) is a well-known but infrequent side effect of inhaled anesthetic use, depolarizing muscle agents, and has not been described in the PICU following the use of anesthetics for pediatric asthma.

show abstract

Section: Discussionmentioning

confidence: 99%

Inhalational Anesthesia for Near-fatal Pediatric Asthma Complicated by Malignant Hyperthermia

Pasrija¹,

Assioun²,

Sallam³

et al. 2021

Cureus

View full text Add to dashboard Cite

show abstract

“…Malignant hyperthermia is usually associated with inhaled anaesthetics and succinylcholine 10. There are a few reports of malignant hyperthermia in skeletal dysplasia 11 12.…”

Section: Discussionmentioning

confidence: 99%

Campomelic dysplasia and malignant hyperthermia

Barros

Teixeira²,

Camacho³

et al. 2011

Case Reports

View full text Add to dashboard Cite

Campomelic dysplasia (CD) is a rare clinical entity, usually fatal in the first year of life. It is characterised by bowing and angulations of long bones, along with other congenital anomalies. The occurrence of malignant hyperthermia is rare, but it has been associated with skeletal dysplasias. The authors present the case of a boy, born at 40 weeks of gestational age, with multiple congenital anomalies and subsequently diagnosed with CD, who died at 16 months of age as a consequence of malignant hyperthermia.

show abstract

Malignant Hyperthermia

Brandom¹,

Visoiu²

2011

Pediatric Critical Care

View full text Add to dashboard Cite

Hyperthermia in the pediatric intensive care unit – is it malignant hyperthermia?

Cited by 4 publications

References 16 publications

Inhalational Anesthesia for Near-fatal Pediatric Asthma Complicated by Malignant Hyperthermia

Inhalational Anesthesia for Near-fatal Pediatric Asthma Complicated by Malignant Hyperthermia

Campomelic dysplasia and malignant hyperthermia

Malignant Hyperthermia

Contact Info

Product

Resources

About